Curis Lifesciences Ltd.
CURISSME
Ask IPO
Overview
Curis Lifesciences Limited is a pharmaceutical manufacturer specializing in a diverse range of products including tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments. Originating as a partnership firm in 2010, the company has evolved to operate through multiple business verticals: loan license manufacturing, contract manufacturing for domestic suppliers and merchant exporters, and direct exports of its own brands. Curis Lifesciences primarily serves domestic markets but also has a presence in international territories like the Republic of Yemen and Kenya through direct exports, and numerous other countries via merchant exporters. The company's manufacturing facility in Gujarat is WHO-GMP certified and holds approvals for several international health authorities.
Opening Date
Nov 07, 2025
Closing Date
Nov 11, 2025
Listing Date
Nov 14, 2025
IPO Type
SME
IPO Status
Closed
Issue Size
27.52 Cr
Fresh Issue
27.52 Cr
Offer for Sale
0 Cr
Price Band
₹120 - ₹128
Lot Size
1000
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
IPO Objective
Our Company intends to utilize the Net Proceeds from the Issue for the following objects:
- •
Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities to enhance automation in testing and packaging processes, aiming to increase productivity and efficiency.
- •
Capital Expenditure towards Construction of a new Storage Facility to support expanded manufacturing operations and inventory management.
- •
Pre-payment or Repayment of a portion of outstanding Secured Loans to reduce debt servicing costs and strengthen the balance sheet.
- •
Funding the expenses related to Product Registrations in various other countries to expand the company's direct export and own-brand manufacturing business vertical.
- •
To meet the growing Working Capital Requirements of the business, driven by an increase in the scale of operations.
- •
To fund General Corporate Purposes, which may include strategic initiatives, brand-building exercises, and meeting unforeseen business exigencies.
Key Performance Indicator
P/E Ratio
—
EPS
—
ROE
55.25%
ROCE
27.83%
RONW
37.62%
Debt to Equity Ratio
—
PAT Margin
12.43%
EBITDA Margin
19.41%
P/B
12.64
SWOT Analysis
Strengths
- •
Diverse product portfolio including tablets, capsules, oral liquids, and ointments.
- •
Flexible business model with multiple revenue streams: loan license, contract manufacturing, and direct exports.
- •
Manufacturing facility is WHO-GMP certified with approvals from regulatory bodies in Kenya, Yemen, Philippines, and Nigeria.
- •
Established relationships with a broad clientele of domestic and international pharma marketers.
Weaknesses
- •
High concentration of manufacturing operations at a single facility in Sanand, Gujarat, posing operational risks.
- •
Significant revenue dependence on a limited number of key customers.
- •
History of delays in the repayment of loan installments, which could impact creditworthiness.
- •
Operations are conducted from a leased registered office, which does not provide long-term asset security.
Opportunities
- •
Leverage IPO proceeds to upgrade manufacturing facilities and build a new storage facility, enhancing production capacity and efficiency.
- •
Expand direct export business by obtaining product registrations in new international markets.
- •
Capitalize on the growing Indian pharmaceutical market, which is projected to reach approximately $130 billion by 2030.
- •
Benefit from government initiatives like the Production Linked Incentive (PLI) scheme to boost domestic manufacturing.
Threats
- •
Subject to a highly regulated industry with stringent quality standards and the need for continuous renewal of licenses and approvals.
- •
Vulnerability to fluctuations in raw material prices due to the absence of long-term supply agreements.
- •
Intense competition from both large multinational corporations and smaller unorganized local players.
- •
Exposure to global economic uncertainties and foreign currency exchange rate fluctuations that could impact export revenues and profitability.
Subscription Rate
Frequently Asked Questions about Curis Lifesciences Ltd.
Curis Lifesciences Limited is a pharmaceutical manufacturer specializing in a diverse range of products including tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments. Originating as a partnership firm in 2010, the company has evolved to operate through multiple business verticals: loan license manufacturing, contract manufacturing for domestic suppliers and merchant exporters, and direct exports of its own brands. Curis Lifesciences primarily serves domestic markets but also has a presence in international territories like the Republic of Yemen and Kenya through direct exports, and numerous other countries via merchant exporters. The company's manufacturing facility in Gujarat is WHO-GMP certified and holds approvals for several international health authorities.
The Curis Lifesciences Ltd. IPO is scheduled to open for subscription on Nov 07, 2025 and close on Nov 11, 2025. Investors can apply for shares during this period through eligible platforms.
The price band for the Curis Lifesciences Ltd. IPO is ₹120 to ₹128. Investors can place bids within this range once the issue opens.
The minimum lot size for the Curis Lifesciences Ltd. IPO is 1000 shares. The minimum investment amount ₹1,28,000.
The total issue size of the Curis Lifesciences Ltd. IPO is approximately ₹27.52. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Curis Lifesciences Ltd. IPO has been subscribed 5.15 times. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Curis Lifesciences Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Curis Lifesciences Ltd. are expected to list on stock exchanges on Nov 14, 2025, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Curis Lifesciences Ltd. IPO are proposed to be used for Our Company intends to utilize the Net Proceeds from the Issue for the following objects:, Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities to enhance automation in testing and packaging processes, aiming to increase productivity and efficiency., Capital Expenditure towards Construction of a new Storage Facility to support expanded manufacturing operations and inventory management., Pre-payment or Repayment of a portion of outstanding Secured Loans to reduce debt servicing costs and strengthen the balance sheet., Funding the expenses related to Product Registrations in various other countries to expand the company's direct export and own-brand manufacturing business vertical., To meet the growing Working Capital Requirements of the business, driven by an increase in the scale of operations., To fund General Corporate Purposes, which may include strategic initiatives, brand-building exercises, and meeting unforeseen business exigencies.
Before applying for the Curis Lifesciences Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
